These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19507469)

  • 1. Combined therapy with amphotericin B and caspofungin in an experimental model of disseminated histoplasmosis.
    Rodríguez-Arellanes G; Taylor ML; Pérez-Torres A; Curiel-Quesada E; Vargas-Mendoza CF; Martínez-Rivera MA
    Rev Invest Clin; 2009; 61(1):4-10. PubMed ID: 19507469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the therapeutic activity of caspofungin compared with the amphotericin B in an animal experimental model of histoplasmosis in hamster (Mesocrisetus auratus).
    Finquelievich J; Landaburu MF; Pinoni V; Iovannitti CA
    Rev Iberoam Micol; 2011; 28(4):155-8. PubMed ID: 21473926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal susceptibility profile and correlation of mycelial and yeast forms of molecularly characterized Histoplasma capsulatum strains from India.
    Kathuria S; Singh PK; Meis JF; Chowdhary A
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5613-6. PubMed ID: 24982084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.
    Kohler S; Wheat LJ; Connolly P; Schnizlein-Bick C; Durkin M; Smedema M; Goldberg J; Brizendine E
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1850-4. PubMed ID: 10858342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
    Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
    J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A proposal for antifungal epidemiological cut-off values against Histoplasma capsulatum var. capsulatum based on the susceptibility of isolates from HIV-infected patients with disseminated histoplasmosis in Northeast Brazil.
    Brilhante RSN; Guedes GMM; Silva MLQD; Castelo-Branco DSCM; Cordeiro RA; Sidrim JJC; Rocha MFG
    Int J Antimicrob Agents; 2018 Aug; 52(2):272-277. PubMed ID: 29592837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental chemotherapy of histoplasmosis in nude mice.
    Williams DM; Graybill JR; Drutz DJ
    Am Rev Respir Dis; 1979 Oct; 120(4):837-42. PubMed ID: 507510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum.
    Hage CA; Connolly P; Horan D; Durkin M; Smedema M; Zarnowski R; Smith P; Wheat LJ
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4447-50. PubMed ID: 21670186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model.
    González GM; González G; Najvar LK; Graybill JR
    J Antimicrob Chemother; 2007 Dec; 60(6):1341-6. PubMed ID: 17934204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
    Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
    J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histoplasmosis in HIV-positive patients in Ceará, Brazil: clinical-laboratory aspects and in vitro antifungal susceptibility of Histoplasma capsulatum isolates.
    Brilhante RS; Fechine MA; Mesquita JR; Cordeiro RA; Rocha MF; Monteiro AJ; Lima RA; Caetano ÉP; Pereira JF; Castelo-Branco DS; Camargo ZP; Sidrim JJ
    Trans R Soc Trop Med Hyg; 2012 Aug; 106(8):484-8. PubMed ID: 22703696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis.
    Bocanegra R; Najvar LK; Hernandez S; McCarthy DI; Graybill JR
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5139-41. PubMed ID: 16304187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection.
    Haynes RR; Connolly PA; Durkin MM; LeMonte AM; Smedema ML; Brizendine E; Wheat LJ
    J Infect Dis; 2002 Jun; 185(12):1830-2. PubMed ID: 12085335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of interferon-gamma and amphotericin B for the treatment of systemic murine histoplasmosis.
    Clemons KV; Lutz JE; Stevens DA
    Microbes Infect; 2001 Jan; 3(1):3-10. PubMed ID: 11226849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants.
    Mohamed WA; Ismail M
    J Trop Pediatr; 2012 Feb; 58(1):25-30. PubMed ID: 21355042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of histoplasmosis with MK-991 (L-743,872).
    Graybill JR; Najvar LK; Montalbo EM; Barchiesi FJ; Luther MF; Rinaldi MG
    Antimicrob Agents Chemother; 1998 Jan; 42(1):151-3. PubMed ID: 9449276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.
    Connolly P; Wheat LJ; Schnizlein-Bick C; Durkin M; Kohler S; Smedema M; Goldberg J; Brizendine E; Loebenberg D
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2604-8. PubMed ID: 10991831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B therapy of murine histoplasmosis.
    Graybill JR; Bocanegra R
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1885-7. PubMed ID: 7486941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin.
    van Duin D; Casadevall A; Nosanchuk JD
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3394-400. PubMed ID: 12384341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.